<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544959</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-09-174</org_study_id>
    <secondary_id>CAS-008-2010</secondary_id>
    <nct_id>NCT01544959</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesia Impact of Narcotic Free Anesthesia</brief_title>
  <acronym>PAINFree</acronym>
  <official_title>The Impact on Postoperative Pain of Substituting Opioids by Beta Blockers for Peroperative Hemodynamic Control in Patients Undergoing Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first hypothesis of the study is that substituting fentanyl by esmolol and metoprolol
      during general anesthesia for patients undergoing mastectomy will result in less pain and
      less narcotic consumption in the recovery room. The investigators will also verify the impact
      of that substitution on nausea and vomiting, on the time spent in the recovery room and on
      chronic postsurgical pain (3 and 6 months).

      Finally, the investigators will see the impact on breast cancer recurrence 5 years after the
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative consumption of narcotic in recovery room</measure>
    <time_frame>Immediately after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain level in recovery room</measure>
    <time_frame>immediately after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of nausea and vomiting in the recovery room</measure>
    <time_frame>immediately after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in recovery room</measure>
    <time_frame>immediately after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic post-surgical pain</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reccurence of breast cancer</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Breast Cancer</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>beta-blocker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.</description>
    <arm_group_label>fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta-blocker (esmolol, metropolol)</intervention_name>
    <description>esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.</description>
    <arm_group_label>beta-blocker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman

          -  18 to 65 years old

          -  ASA 1 or 2

          -  First breast surgery

          -  Unilateral breast cancer

          -  Partial mastectomy or radical modified mastectomy ± axillary dissection

        Exclusion Criteria:

          -  Allergy or contrindication to any medication figuring in the protocol or to Aspirin

          -  Patient taking betablocking drug drug or lanoxin or calcic channels blocking drug

          -  Narcotic consumption in the past month of 10 mg/day of morphine equivalent

          -  Chronic pain

          -  Moderate to severe asthma

          -  BMI of more than 40

          -  Diabetes

          -  Chronic renal or hepatic faiure

          -  Heart failure

          -  Anticipated difficult airway

          -  High grade heart block or bifascicular block

          -  Mental retardation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne de Medicis, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Etienne de Medicis</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Narcotic</keyword>
  <keyword>Opioid</keyword>
  <keyword>betablocking drug</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>postoperative nausea and vomiting</keyword>
  <keyword>breast cancer</keyword>
  <keyword>hyperalgesia</keyword>
  <keyword>cancer recurrence</keyword>
  <keyword>anesthesia</keyword>
  <keyword>mastectomy</keyword>
  <keyword>chronic postsurgical pain syndrome</keyword>
  <keyword>acute postoperative pain</keyword>
  <keyword>postmastectomy pain syndrome</keyword>
  <keyword>pain</keyword>
  <keyword>ambulatory surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Narcotics</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

